SG
Therapeutic Areas
Legend Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CARVYKTI (ciltacabtagene autoleucel) | Relapsed/Refractory Multiple Myeloma | Approved |
| LB1901 | Relapsed/Refractory T-cell Lymphoma (Adult T-cell Leukemia/Lymphoma) | Phase 1 |
| LB2102 | Extensive-Stage Small Cell Lung Cancer (SCLC) | Phase 1 |
| LB1908 | Gastric, Pancreatic, and Colorectal Cancers | Phase 1 |
| LB-ALLO1 | Relapsed/Refractory Multiple Myeloma | Pre-clinical |
Leadership Team at Legend Biotech
DY
Dr. Ying Huang
Chief Executive Officer & Chief Financial Officer
DL
Dr. Lida Pacaud
Chief Medical Officer
DF
Dr. Frank Zhang
Chief Scientific Officer
LM
Lori Macomber
Chief Legal Officer & Corporate Secretary
PB
Pranoti Bhave
Vice President, Clinical Development
DR
Dr. Robert Azelby
Chairman of the Board of Directors
DL
Dr. Lei Xiao
Founder & Director
DR
Dr. R. Keith Woods
Director
DJ
Dr. Jane Pritchett Henderson
Director
DR
Dr. Robin L. Smith
Director